Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Bensinger

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2002
Infectious complications after autologous CD34-selected peripheral blood stem cell transplantationFulvio Crippa, Leona Holmberg, Rachel A Carter, et al.
Blood|September 10, 2013
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaMichael Wang, Tom Martin, William Bensinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial resultsLinda S Elting, Ya-Chen Tina Shih, Patrick J Stiff, et al.
Blood|February 22, 2003
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimenJerald P Radich, Ted Gooley, William Bensinger, et al.
Blood|March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myelomaJoseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
British Journal of Haematology|August 7, 2012
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myelomaWilliam Bensinger, Richard T Maziarz, Sundar Jagannath, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcomeLeona Holmberg, Kaoru Kikuchi, Ted A Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 14, 2011
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantationAbraham Guerrero, Stanley R Riddell, Jan Storek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myelomaHenk Lokhorst, Hermann Einsele, David Vesole, et al.
Leukemia & Lymphoma|May 3, 2008
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaBrian G Till, Theodore A Gooley, Nathan Crawford, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 18, 2002
Infectious complications after autologous CD34-selected peripheral blood stem cell transplantationFulvio Crippa, Leona Holmberg, Rachel A Carter, et al.
Blood|September 10, 2013
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myelomaMichael Wang, Tom Martin, William Bensinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial resultsLinda S Elting, Ya-Chen Tina Shih, Patrick J Stiff, et al.
Blood|February 22, 2003
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimenJerald P Radich, Ted Gooley, William Bensinger, et al.
Blood|March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myelomaJoseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
British Journal of Haematology|August 7, 2012
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myelomaWilliam Bensinger, Richard T Maziarz, Sundar Jagannath, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 31, 2006
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcomeLeona Holmberg, Kaoru Kikuchi, Ted A Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 14, 2011
Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantationAbraham Guerrero, Stanley R Riddell, Jan Storek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myelomaHenk Lokhorst, Hermann Einsele, David Vesole, et al.
Leukemia & Lymphoma|May 3, 2008
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphomaBrian G Till, Theodore A Gooley, Nathan Crawford, et al.
Pageof 5